Helen M. Conaglen

CHILD PEDESTRIANS' CROSSING GAP THRESHOLDS

Three gender-balanced groups of 16 school children (5-6 years, 8-9 years, 11-12 years) participated in individual pretests of vision, hearing, and time to walk across a 12-m wide urban street and back. Each child then completed 10 roadside trials requiring judgement of the threshold point at which they would no longer cross in front of traffic approaching from their right. The judgements were made from a site immediately in front of a parked car at a point 2 m from the kerb and 4 m from the centre of the road. Traffic speeds and distances were measured using a laser speed and distance detector. The results indicated that, overall, distance gap thresholds remained constant regardless of vehicle approach speeds. Analysis of the thresholds for distance gap judgements for the 4-m half-street crossing showed that some of the older children could be expected to make safe decisions, but this was not so for the 5-6- and 8-9-year-olds at vehicle approach speeds above 60 kph. Almost two-thirds of the children reported using distance to judge gaps, which proved the least adequate strategy in terms of proportion of resultant safe decisions. The findings are discussed in relation to developing effective child pedestrian safety strategies.

The effect of gynecological surgery on sexual desire.

This study compared the impact of surgery on sexual desire in women who had undergone hysterectomy with women whose nongynecological surgery was of a similar status. Women aged 30 to 65 completed mailed questionnaires including the Sexual Desire Questionnaire, Hurlbert Index of Sexual Desire, and the Sexual Desire Inventory. Other areas assessed were affect, mood awareness, sexual anxiety, and androgen levels. Analysis of the questionnaire measures showed no differences in sexual desire for gynecological versus nongynecological surgery, or across the different types of hysterectomy. There was no relation between the level of androgens and the womens sexual desire levels. The implications of these findings are discussed with regard to the potential impact of surgery on sexuality, as well as future research in the area.

A prospective study of the psychological impact on patients of first diagnosis of human papillomavirus.

This study assessed the psychological impact of the first time diagnosis of human papillomavirus (HPV) in consecutive clients attending the Hamilton Sexual Health Clinic, and sought to determine whether this changed over time. Clients with a diagnosis other than HPV and those found to have no diagnosis were compared with HPV clients. All participants completed a battery of questionnaires following their initial visit and again at 4 weeks. The battery consisted of the General Health Questionnaire, Illness Attitude Scales, the International Index of Erectile Function or the Brief Index of Sexual Function for Women, and a 6-question test of the clients knowledge of HPV. One hundred and one participants completed the first questionnaires and 47 of those completed follow-up questionnaires. We found those diagnosed with first episode of HPV had considerable psychological difficulties. However these were no different to those associated with other sexually transmitted infections (STIs) or even those with no active diagnosis.

The effects of treating male hypogonadism on couples' sexual desire and function.

INTRODUCTION Hypogonadism is a common endocrine condition characterized by low levels of testosterone (T) and marked by numerous symptoms, one of which is low sexual desire. Studies comparing T delivery systems have suggested that hypogonadal mens partners may be at risk from exposure to T gels. Little other mention is found of the impact of hypogonadism and its treatment on a mans partner and the couples sexual function. AIM To assess sexual desire and sexual function in hypogonadal men and their woman partners before and after treatment with T replacement therapy. METHODS Twenty-one hypogonadal men and 18 partners were recruited from a tertiary endocrine clinic, and were compared with a control group of 20 eugonadal age-matched men and their partners. All men had baseline blood tests to confirm their status as hypogonadal or eugonadal, and hypogonadal men repeated tests at 3-month intervals. All participants completed the Sexual Desire Inventory (SDI) and sexual function questionnaires at baseline and at 3-month intervals until the hypogonadal men attained normal T levels. MAIN OUTCOME MEASURES Pre- and post-treatment SDI and sexual function questionnaires were compared once T normalization was achieved. Between- and within-group comparisons were carried out. RESULTS Pretreatment hypogonadal men recorded lower levels of sexual desire and function than controls, but significantly improved once hypogonadism was corrected. Eugonadal controls recorded no significant changes in either sexual desire or function during the study. Partners of the hypogonadal men reported no changes on the SDI, but significant improvements in sexual function as their partners recovered. CONCLUSION SDI and sexual function measures reflect sexual changes that accompany rising serum T levels during correction of male hypogonadism. Women partners reported more satisfaction, less pain, and improved sexual function following the mens treatment. Treatments affecting one partner potentially have important effects on the other.

Sexual Desire in Women Presenting for Antiandrogen Therapy

Women presenting with hirsuties/polycystic ovary syndrome have increased production of androgens. Clinical lore suggests that these women may have increased sexual desire. Treatment of hirsuties commonly involves antiandrogen therapy, a form of therapy with a potential for reducing sexual desire. The present study investigated sexual desire in 29 hirsute women aged 19 to 43 years presenting for therapy. We conducted a questionnaire appraisal of the women’s sexual desire, body and self-esteem, and affect at baseline, 3 months, and 12 months and compared the data with a control group of 30 nonhirsute women of similar mean age. Those in the treatment group also had their Ferriman and Gallwey scores and body mass indices calculated at baseline and end of study for those in the treatment group. We determined hormone levels for those in the treatment group with baseline blood tests. Our hypotheses were that the hirsute women would experience different levels of sexual desire than the control group prior to therapy and that therapy would have a demonstrable effect on the self-reported sexual desire of these women. The study demonstrated that women with hirsuties had mean levels of sexual desire and body esteem that were significantly lower than the control group women. During the year-long course of therapy, the sexual desire levels of the hirsute women decreased progressively, while their self-esteem increased. The women’s Ferriman and Gallwey scores fell, indicating diminishing hirsutism. These findings provide empirical data upon which clinicians can base advice to patients seeking therapy.

Effect of deer velvet on sexual function in men and their partners: a double-blind, placebo-controlled study.

The use of alternative medicines and herbal remedies is an increasing trend in Western societies. For years, people have taken products made of deer velvet for their alleged beneficial effects on sexual function. There has been no scientific investigation of the effects of deer velvet powder on the sexual functioning of human males. This study investigated sexual function in men during a 12-week double-blind, placebo-controlled trial of deer velvet. Thirty-two volunteer male participants, aged 45–65 years, and their partners, were randomly assigned to either the deer velvet or placebo study group. The males took capsules containing ground deer velvet or placebo everyday for 12 weeks. Two sexual function questionnaires (the International Index of Erectile Function and the Brief Index of Sexual Function for Women) used at pre- and posttreatment assessed changes in sexual functioning in males and their partners. Blood tests at baseline, and end of study, determined levels of sex-related hormones in male participants. There were no significant differences in the sexual behavior of the men taking deer velvet compared with the men taking placebo capsules. There were no significant hormone changes from baseline to the end of the study in either group of men. We conclude that in normal males there was no advantage in taking deer velvet to enhance sexual function. All alternative health products or nutritional supplements should be subjected to randomized placebo-controlled trials to determine efficacy.